Company intelligence / Profile preview

CannaVest Europe

San Diego, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

CV Sciences, formerly known as CannaVest Corp, is a consumer wellness and pharmaceutical company focused on hemp-derived cannabidiol (CBD) products. The company operates through two primary divisions: a consumer product division that markets the PlusCBD brand and a drug development division focused on cannabinoid-based therapeutics. Their lead pharmaceutical candidate, CVSI-007, is a proprietary combination of CBD and nicotine designed to assist in smokeless tobacco cessation. CV Sciences is a pioneer in the hemp industry, having established one of the first large-scale supply chains for hemp-derived CBD in the United States and Europe.

Therapeutic areas: PsychiatryImmunologyNeurology
Modalities: Small moleculePlant-derived extract
Industry: Biotech

Beyond the preview

Go deeper on CannaVest Europe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CannaVest Europe.

Explore the full profile